Dexcom (DXCM)
Builds continuous glucose monitors for diabetes care and broader metabolic-health tracking.
Something off on this page? Send us feedback.
Produces continuous glucose monitors for diabetes and metabolic health, led by prescription G7 systems and the over-the-counter Stelo biosensor. Revenue comes mainly from recurring disposable-sensor sales in the United States, supported by apps, cloud reporting, and insulin-delivery integrations, with access tied to device approvals and reimbursement.
Designs and sells wearable continuous glucose monitoring systems that send glucose readings and alerts to apps, receivers, and connected insulin-delivery devices. The prescription portfolio is shifting from Dexcom G6 to Dexcom G7 and G7 15 Day, while Dexcom ONE+ serves selected international markets and Stelo brings over-the-counter glucose sensing to people who do not use insulin. Most revenue comes from the United States, through distributors and direct channels.
Combines disposable sensors with reusable hardware, cloud reporting, remote-sharing software, and integrations with insulin pumps and smart pens. Frequent sensor replacement creates recurring product demand, while connected-device compatibility broadens how readings support care. Commercial access depends on medical-device clearances and public and private reimbursement; manufacturing quality is tightly regulated, and some components come from single or sole sources.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | Truist Financial | Target | Target: $93 | Target: $102 |
| Aug 4, 2026 | Argus Research | Reiterate | Rating: —Target: — | Target: $96 |
| Aug 3, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $82 | Target: $90 |
| Aug 3, 2026 | RBC Capital | Target | Target: $85 | Target: $90 |
| Jul 31, 2026 | Raymond James | Reiterate | Rating: —Target: $91 | Target: $94 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.95B · Total debt $1.40B · Total assets $6.46B · Shareholders' equity $2.62B
- Revenue
- $1.31B
- Operating income
- $318.3M
- Net income
- $249.1M
No dividends on record.
| Institutions | ≈ 103.06% | 388.91M shares | |
|---|---|---|---|
| 1,023 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.52% | 1.95M shares | |
| 20 holders · as of Sep 16, 2026 | |||
| Adds to | 103.58% | ||
377.36M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 103.58%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.13% | 38.24M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.68% | 25.21M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.21% | 19.66M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.87% | 18.38M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 4.05% | 15.29M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Michael Jon Brown | officer: EVP Chief Legal Compliance Off | −1,700 | $84.04 |
| Sep 15, 2026 | Nicholas Augustinos | director | −6,539 | $84.04 |
| Sep 14, 2026 | Nicholas Augustinos | director | −1,550 | $84.02 |
| Sep 10, 2026 | Jereme M. Sylvain | officer: EVP, Chief Financal Officer | −3,638 | $83.27 |
| Aug 27, 2026 | Sadie Stern | officer: EVP Chief People & Culture Off | −2,565 | $88.37 |
- Abbott
Global CGM leader; Lingo and Libre Rio contest Stelo directly.
- Medtronic
MiniMed 780G AID + Simplera/Instinct CGM; diabetes unit spinning out.
- Insulet
Omnipod 5 AID pump: integrates both DexCom G6/G7 and Abbott Libre.
- Tandem Diabetes Care
t:slim / Mobi AID pumps support DexCom and Abbott CGMs; $1B in 2025.
- Senseonics
Eversense 365: only 1-year implantable iCGM; 49.5% patients from DexCom.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dexcom | $88.44 | −0.82% | $33.65B | 35.2 | 31.5 | 6.8 | +13.1% |
| Abbott | $104.04 | +1.03% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Medtronic | $91.35 | −0.44% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Insulet | $137.97 | −1.82% | $9.73B | 26.3 | 20.0 | 3.2 | +23.5% |
| Tandem Diabetes Care | $17.08 | −3.09% | $1.21B | — | — | 1.2 | +5.8% |
| Senseonics | $9.59 | −1.94% | $408.7M | — | — | 8.4 | +118.1% |
| Median | 26.3 | 18.0 | 3.2 | +13.7% |